Ketogenic Diets as an Adjuvant Therapy in Glioblastoma
Atslēgvārdi
Abstrakts
Apraksts
A prospective, non-blinded, randomized, pilot study will be undertaken in patients with glioblastoma (GB). Patients will be randomized to the modified ketogenic diet (MKD) or the medium chain triglyceride ketogenic diet (MCT) for a 12 week period (primary completion). If patients wish to remain on diet, they will be offered dietetic support for a total of 12 months (secondary completion).
The trial will be open to all Walton Centre Foundation Trust patients with a newly diagnosed GB, who have undergone surgical resection or biopsy within the last four months and who are going on to receive/ are currently receiving/ have completed oncological treatments (radiotherapy or chemotherapy or chemoradiotherapy). Patients will be referred via neuro-oncology multi-disciplinary meetings and neurosurgical clinics, post histology. The diet will be offered alongside standard care, commencing within four months of surgery.
Both diets are high in fat and low in carbohydrate, but contain different types and amounts of fats. The MKD is 80% fat (predominately long chain fatty acids) and 5% carbohydrate, whilst the MCT diet is 75% fat (30% of which is medium chain fatty acids) and 10% carbohydrate.
A permuted block randomization method will be adopted, using 'sealedenvelope' randomization system. This will be set up and administered by the statistician, who is not involved with the recruiting of patients.
Patients will receive regular input from the trial dietitian. This includes clinical consultations at baseline, dietary initiation, week 6, week 12 and every 3 months thereafter and telephone consultations at weeks 1, 3 and 9. Patients will receive dietary and ketone monitoring education.
Assessments and monitoring undertaken at each consultation include anthropometry, biochemistry, compliance, tolerance, acceptability, quality of life and ketosis.
Informed consent will be obtained prior to enrollment and the patient may withdraw at any time.
An information study is also embedded into KEATING, to aid understanding of the patients' recruitment experience and viewpoints, by interviewing a sub-sample of patients and their relatives/ carers. This will enable the design of bespoke strategies to optimise recruitment to future trials related to ketogenic diets and gliomas
Datumi
| Pēdējoreiz pārbaudīts: | 03/31/2019 |
| Pirmais iesniegtais: | 02/27/2017 |
| Paredzētā reģistrācija iesniegta: | 03/02/2017 |
| Pirmais izlikts: | 03/08/2017 |
| Pēdējais atjauninājums iesniegts: | 04/01/2019 |
| Pēdējā atjaunināšana ievietota: | 04/03/2019 |
| Faktiskais studiju sākuma datums: | 03/31/2017 |
| Paredzamais primārās pabeigšanas datums: | 03/04/2019 |
| Paredzamais pētījuma pabeigšanas datums: | 03/04/2019 |
Stāvoklis vai slimība
Iejaukšanās / ārstēšana
Other: Modified ketogenic diet (MKD)
Other: Medium chain triglyceride (MCT) diet
Fāze
Roku grupas
| Roka | Iejaukšanās / ārstēšana |
|---|---|
| Active Comparator: Modified ketogenic diet (MKD) MKD: 80% fat and 5% carbohydrate (% of total energy requirements per day). | Other: Modified ketogenic diet (MKD) Modified ketogenic diet |
| Active Comparator: Medium chain triglyceride (MCT) diet MCT: 75% fat (30% of which is medium chain fatty acids taken as a supplement) and 5% carbohydrate (% of total energy requirements per day). | Other: Medium chain triglyceride (MCT) diet Medium chain triglyceride ketogenic diet |
Atbilstības kritēriji
| Vecums, kas piemērots studijām | 16 Years Uz 16 Years |
| Dzimumi, kas ir piemēroti studijām | All |
| Pieņem veselīgus brīvprātīgos | Jā |
| Kritēriji | Inclusion Criteria: - Age ≥16 years - Patient at The Walton Centre NHS Foundation Trust - Performance status ≤2 - Confirmed histological diagnosis of glioblastoma - Undergone surgical resection or biopsy and will go onto receive/ is receiving/ has received oncological treatments Exclusion Criteria: - Having prior use of KD - Kidney dysfunction - Liver dysfunction - Gall bladder dysfunction - Metabolic disorder - Eating disorder - Diabetes (requiring medication) - Body mass index ≤ 18.5kg/m2 - Weight loss medications - Currently pregnant or breast feeding - Performance status ≥3 |
Rezultāts
Primārie rezultāti
1. To assess retention and drop out rates [12 weeks]
2. To assess retention and drop out rates [12 weeks]
3. To assess retention and drop out rates [12 weeks]
4. To assess retention and drop out rates [12 weeks]
Sekundārie iznākuma mērījumi
1. Estimation of recruitment rates [12 months]
2. Enrollment of patients [12 months]
3. Enrollment of patients [12 months]
4. Enrollment of patients [12 months]
5. Long term retention [2 years]
6. Dietary adjustments required to achieve ketosis [2 years]
7. Self reported dietary compliance [2 years]
8. Calculated dietary compliance [2 years]
9. MCT compliance [2 years]
10. Ketosis levels [2 years]
11. Dietetic time required for interventions [2 years]
12. Protocol refinements required [2 years]
13. Sample size estimates for future trials [2 years]
14. Quality of life [2 years]
15. Food acceptability [2 years]
16. Gastrointestinal side effects [2 years]
17. Changes to biochemical markers [2 years]
18. Anthropometric changes [2 years]
19. Completeness of data [2 years]
